Medical Expenditures and Earnings Losses Among US Adults With Arthritis in 2013
Objective We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data. Methods We calculated arthritis‐attributable and all‐cause medical expenditures for adults age ≥18 years and arthritis‐attributable earnings losses among those ages 18–64 years who had...
Saved in:
| Published in: | Arthritis care & research (2010) Vol. 70; no. 6; pp. 869 - 876 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.06.2018
|
| Subjects: | |
| ISSN: | 2151-464X, 2151-4658, 2151-4658 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Objective
We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.
Methods
We calculated arthritis‐attributable and all‐cause medical expenditures for adults age ≥18 years and arthritis‐attributable earnings losses among those ages 18–64 years who had ever worked. We calculated arthritis‐attributable costs using multistage regression‐based methods, and conducted sensitivity analyses to estimate costs for 2 other arthritis definitions in MEPS.
Results
In 2013, estimated total national arthritis‐attributable medical expenditures were $139.8 billion (range $135.9–$157.5 billion). Across expenditure categories, ambulatory care expenditures accounted for nearly half of arthritis‐attributable expenditures. All‐cause expenditures among adults with arthritis represented 50% of the $1.2 trillion national medical expenditures among all US adults in MEPS. Estimated total national arthritis‐attributable earning losses were $163.7 billion (range $163.7–$170.0 billion). The percentage with arthritis who worked in the past year was 7.2 percentage points lower than those without arthritis (76.8% [95% confidence interval (95% CI)] 75.0–78.6 and 84.0% [95% CI 82.5–85.5], respectively, adjusted for sociodemographics and chronic conditions). Total arthritis‐attributable medical expenditures and earnings losses were $303.5 billion (range $303.5–$326.9 billion).
Conclusion
Total national arthritis‐attributable medical care expenditures and earnings losses among adults with arthritis were $303.5 billion in 2013. High arthritis‐attributable medical expenditures might be reduced by greater efforts to reduce pain and improve function. The high earnings losses were largely attributable to the substantially lower prevalence of working among those with arthritis compared to those without, signaling the need for interventions that keep people with arthritis in the workforce. |
|---|---|
| AbstractList | Objective
We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.
Methods
We calculated arthritis‐attributable and all‐cause medical expenditures for adults age ≥18 years and arthritis‐attributable earnings losses among those ages 18–64 years who had ever worked. We calculated arthritis‐attributable costs using multistage regression‐based methods, and conducted sensitivity analyses to estimate costs for 2 other arthritis definitions in MEPS.
Results
In 2013, estimated total national arthritis‐attributable medical expenditures were $139.8 billion (range $135.9–$157.5 billion). Across expenditure categories, ambulatory care expenditures accounted for nearly half of arthritis‐attributable expenditures. All‐cause expenditures among adults with arthritis represented 50% of the $1.2 trillion national medical expenditures among all US adults in MEPS. Estimated total national arthritis‐attributable earning losses were $163.7 billion (range $163.7–$170.0 billion). The percentage with arthritis who worked in the past year was 7.2 percentage points lower than those without arthritis (76.8% [95% confidence interval (95% CI)] 75.0–78.6 and 84.0% [95% CI 82.5–85.5], respectively, adjusted for sociodemographics and chronic conditions). Total arthritis‐attributable medical expenditures and earnings losses were $303.5 billion (range $303.5–$326.9 billion).
Conclusion
Total national arthritis‐attributable medical care expenditures and earnings losses among adults with arthritis were $303.5 billion in 2013. High arthritis‐attributable medical expenditures might be reduced by greater efforts to reduce pain and improve function. The high earnings losses were largely attributable to the substantially lower prevalence of working among those with arthritis compared to those without, signaling the need for interventions that keep people with arthritis in the workforce. We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data. We calculated arthritis-attributable and all-cause medical expenditures for adults age ≥18 years and arthritis-attributable earnings losses among those ages 18-64 years who had ever worked. We calculated arthritis-attributable costs using multistage regression-based methods, and conducted sensitivity analyses to estimate costs for 2 other arthritis definitions in MEPS. In 2013, estimated total national arthritis-attributable medical expenditures were $139.8 billion (range $135.9-$157.5 billion). Across expenditure categories, ambulatory care expenditures accounted for nearly half of arthritis-attributable expenditures. All-cause expenditures among adults with arthritis represented 50% of the $1.2 trillion national medical expenditures among all US adults in MEPS. Estimated total national arthritis-attributable earning losses were $163.7 billion (range $163.7-$170.0 billion). The percentage with arthritis who worked in the past year was 7.2 percentage points lower than those without arthritis (76.8% [95% confidence interval (95% CI)] 75.0-78.6 and 84.0% [95% CI 82.5-85.5], respectively, adjusted for sociodemographics and chronic conditions). Total arthritis-attributable medical expenditures and earnings losses were $303.5 billion (range $303.5-$326.9 billion). Total national arthritis-attributable medical care expenditures and earnings losses among adults with arthritis were $303.5 billion in 2013. High arthritis-attributable medical expenditures might be reduced by greater efforts to reduce pain and improve function. The high earnings losses were largely attributable to the substantially lower prevalence of working among those with arthritis compared to those without, signaling the need for interventions that keep people with arthritis in the workforce. We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.OBJECTIVEWe estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.We calculated arthritis-attributable and all-cause medical expenditures for adults age ≥18 years and arthritis-attributable earnings losses among those ages 18-64 years who had ever worked. We calculated arthritis-attributable costs using multistage regression-based methods, and conducted sensitivity analyses to estimate costs for 2 other arthritis definitions in MEPS.METHODSWe calculated arthritis-attributable and all-cause medical expenditures for adults age ≥18 years and arthritis-attributable earnings losses among those ages 18-64 years who had ever worked. We calculated arthritis-attributable costs using multistage regression-based methods, and conducted sensitivity analyses to estimate costs for 2 other arthritis definitions in MEPS.In 2013, estimated total national arthritis-attributable medical expenditures were $139.8 billion (range $135.9-$157.5 billion). Across expenditure categories, ambulatory care expenditures accounted for nearly half of arthritis-attributable expenditures. All-cause expenditures among adults with arthritis represented 50% of the $1.2 trillion national medical expenditures among all US adults in MEPS. Estimated total national arthritis-attributable earning losses were $163.7 billion (range $163.7-$170.0 billion). The percentage with arthritis who worked in the past year was 7.2 percentage points lower than those without arthritis (76.8% [95% confidence interval (95% CI)] 75.0-78.6 and 84.0% [95% CI 82.5-85.5], respectively, adjusted for sociodemographics and chronic conditions). Total arthritis-attributable medical expenditures and earnings losses were $303.5 billion (range $303.5-$326.9 billion).RESULTSIn 2013, estimated total national arthritis-attributable medical expenditures were $139.8 billion (range $135.9-$157.5 billion). Across expenditure categories, ambulatory care expenditures accounted for nearly half of arthritis-attributable expenditures. All-cause expenditures among adults with arthritis represented 50% of the $1.2 trillion national medical expenditures among all US adults in MEPS. Estimated total national arthritis-attributable earning losses were $163.7 billion (range $163.7-$170.0 billion). The percentage with arthritis who worked in the past year was 7.2 percentage points lower than those without arthritis (76.8% [95% confidence interval (95% CI)] 75.0-78.6 and 84.0% [95% CI 82.5-85.5], respectively, adjusted for sociodemographics and chronic conditions). Total arthritis-attributable medical expenditures and earnings losses were $303.5 billion (range $303.5-$326.9 billion).Total national arthritis-attributable medical care expenditures and earnings losses among adults with arthritis were $303.5 billion in 2013. High arthritis-attributable medical expenditures might be reduced by greater efforts to reduce pain and improve function. The high earnings losses were largely attributable to the substantially lower prevalence of working among those with arthritis compared to those without, signaling the need for interventions that keep people with arthritis in the workforce.CONCLUSIONTotal national arthritis-attributable medical care expenditures and earnings losses among adults with arthritis were $303.5 billion in 2013. High arthritis-attributable medical expenditures might be reduced by greater efforts to reduce pain and improve function. The high earnings losses were largely attributable to the substantially lower prevalence of working among those with arthritis compared to those without, signaling the need for interventions that keep people with arthritis in the workforce. ObjectiveWe estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.MethodsWe calculated arthritis‐attributable and all‐cause medical expenditures for adults age ≥18 years and arthritis‐attributable earnings losses among those ages 18–64 years who had ever worked. We calculated arthritis‐attributable costs using multistage regression‐based methods, and conducted sensitivity analyses to estimate costs for 2 other arthritis definitions in MEPS.ResultsIn 2013, estimated total national arthritis‐attributable medical expenditures were $139.8 billion (range $135.9–$157.5 billion). Across expenditure categories, ambulatory care expenditures accounted for nearly half of arthritis‐attributable expenditures. All‐cause expenditures among adults with arthritis represented 50% of the $1.2 trillion national medical expenditures among all US adults in MEPS. Estimated total national arthritis‐attributable earning losses were $163.7 billion (range $163.7–$170.0 billion). The percentage with arthritis who worked in the past year was 7.2 percentage points lower than those without arthritis (76.8% [95% confidence interval (95% CI)] 75.0–78.6 and 84.0% [95% CI 82.5–85.5], respectively, adjusted for sociodemographics and chronic conditions). Total arthritis‐attributable medical expenditures and earnings losses were $303.5 billion (range $303.5–$326.9 billion).ConclusionTotal national arthritis‐attributable medical care expenditures and earnings losses among adults with arthritis were $303.5 billion in 2013. High arthritis‐attributable medical expenditures might be reduced by greater efforts to reduce pain and improve function. The high earnings losses were largely attributable to the substantially lower prevalence of working among those with arthritis compared to those without, signaling the need for interventions that keep people with arthritis in the workforce. |
| Author | Helmick, Charles G. Cisternas, Miriam G. Murphy, Louise B. Pasta, David J. Yelin, Edward H. |
| Author_xml | – sequence: 1 givenname: Louise B. orcidid: 0000-0003-3919-0721 surname: Murphy fullname: Murphy, Louise B. email: lmurphy1@cdc.gov organization: Centers for Disease Control and Prevention – sequence: 2 givenname: Miriam G. surname: Cisternas fullname: Cisternas, Miriam G. organization: MGC Data Services – sequence: 3 givenname: David J. surname: Pasta fullname: Pasta, David J. organization: DMA Corporation – sequence: 4 givenname: Charles G. surname: Helmick fullname: Helmick, Charles G. organization: Centers for Disease Control and Prevention – sequence: 5 givenname: Edward H. surname: Yelin fullname: Yelin, Edward H. organization: University of California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28950426$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU1PGzEQhq0KVD4P_QOVJS5wCPhrvd7jKgpQKSgSLaI3y1nPgtHGG2yvgH-PQ5IeUJnLjEbP-2o07wHa8b0HhH5Qck4JYRemCeeMC1Z8Q_uMFnQkZKF2_s3i7x46jvGJ5OJMKV59R3tMVQURTO6j2Q1Y15gOT16X4K1LQ4CIjbd4YoJ3_iHiaR9j3tWL3j_gu9-4tkOXIr536RHXIT0Gl1zEzmNGKD9Cu63pIhxv-iG6u5z8GV-PprOrX-N6Omp4wYtRW_FGMEtawaEFTg1ITmRbWkpbzotKSUMbC7RkUgJnVAlVlkCNUILMrVT8EJ2ufZehfx4gJr1wsYGuMx76IWpaCS6FrPgKPfmEPvVD8Pk6zYgoM1GyKlM_N9QwX4DVy-AWJrzp7asycLEGmpAfEqDVjUsmud6nYFynKdGrPHTOQ3_kkRVnnxRb0_-xG_cX18Hb16Cux7drxTu0b5Vs |
| CitedBy_id | crossref_primary_10_3390_biomedicines13040987 crossref_primary_10_1002_lary_28648 crossref_primary_10_1007_s00256_020_03386_z crossref_primary_10_5888_pcd22_240393 crossref_primary_10_1111_jep_14195 crossref_primary_10_3390_cells8020085 crossref_primary_10_1016_j_scitotenv_2021_145395 crossref_primary_10_1016_j_actbio_2018_11_014 crossref_primary_10_2106_JBJS_20_01209 crossref_primary_10_3389_fneur_2021_734821 crossref_primary_10_1016_j_acpath_2022_100035 crossref_primary_10_1186_s41927_021_00234_y crossref_primary_10_1002_acr_25340 crossref_primary_10_1007_s00402_024_05252_2 crossref_primary_10_1136_bmjopen_2022_067211 crossref_primary_10_3389_fpubh_2023_1181625 crossref_primary_10_1007_s10067_021_06010_0 crossref_primary_10_3390_app11094053 crossref_primary_10_3389_fpubh_2025_1511860 crossref_primary_10_1007_s11926_022_01061_x crossref_primary_10_2147_CIA_S442259 crossref_primary_10_3389_fgene_2023_1266158 crossref_primary_10_1136_bmjopen_2023_076966 crossref_primary_10_1016_j_knee_2022_09_006 crossref_primary_10_5435_JAAOSGlobal_D_24_00225 crossref_primary_10_1080_17434440_2023_2298729 crossref_primary_10_1002_vms3_70427 crossref_primary_10_1055_s_0041_1735474 crossref_primary_10_1186_s13287_025_04252_2 crossref_primary_10_3390_jcm13154526 crossref_primary_10_1007_s40674_019_00123_z crossref_primary_10_1007_s00256_020_03377_0 crossref_primary_10_3390_geriatrics3040089 crossref_primary_10_1089_scd_2021_0146 crossref_primary_10_1038_s41598_020_63395_9 crossref_primary_10_3389_fpubh_2024_1321860 crossref_primary_10_1136_bmjopen_2023_074391 crossref_primary_10_1002_acr2_11110 crossref_primary_10_1007_s00256_025_05006_0 crossref_primary_10_3390_jcm13226732 crossref_primary_10_15585_mmwr_mm7241a1 crossref_primary_10_3390_nu13020545 crossref_primary_10_1016_j_ijnurstu_2020_103756 crossref_primary_10_1038_s41467_021_21593_7 crossref_primary_10_1007_s11916_021_00947_2 crossref_primary_10_1016_j_bprint_2022_e00239 crossref_primary_10_15585_mmwr_mm7245a1 crossref_primary_10_1016_j_exger_2024_112460 crossref_primary_10_1016_j_arth_2022_02_019 crossref_primary_10_1096_fj_201902698R crossref_primary_10_3389_fimmu_2024_1318737 crossref_primary_10_1016_j_cmpb_2023_107807 crossref_primary_10_3389_fimmu_2024_1362012 crossref_primary_10_1016_j_arthro_2020_05_037 crossref_primary_10_3389_fendo_2022_847401 crossref_primary_10_1002_adhm_202002030 crossref_primary_10_1111_cbdd_13855 crossref_primary_10_1089_ten_tea_2021_0112 crossref_primary_10_1186_s12955_025_02412_9 crossref_primary_10_3390_app14209538 crossref_primary_10_1053_j_semnuclmed_2022_08_010 crossref_primary_10_3390_ijerph19159014 crossref_primary_10_1016_j_gerinurse_2025_103540 crossref_primary_10_1371_journal_pone_0314789 crossref_primary_10_1002_acr2_11065 crossref_primary_10_1177_11795441211016261 crossref_primary_10_1186_s13075_025_03587_8 crossref_primary_10_1002_acr_25515 crossref_primary_10_1016_j_rdc_2022_06_010 crossref_primary_10_15585_mmwr_mm7144a1 crossref_primary_10_2217_nnm_2021_0182 crossref_primary_10_3389_fimmu_2021_734322 crossref_primary_10_5888_pcd19_210277 crossref_primary_10_1002_acr_24381 crossref_primary_10_1016_j_cpet_2022_09_002 crossref_primary_10_26603_001c_142879 crossref_primary_10_3389_fphar_2022_883550 crossref_primary_10_1097_JXX_0000000000000832 crossref_primary_10_3390_nu15010107 crossref_primary_10_1007_s10528_021_10159_3 crossref_primary_10_1097_JOM_0000000000001836 crossref_primary_10_1007_s40744_020_00272_x crossref_primary_10_1016_j_jvn_2021_02_003 crossref_primary_10_1177_0743915620978538 crossref_primary_10_3390_biom15091267 crossref_primary_10_3390_ijms23052743 crossref_primary_10_1016_j_joca_2021_12_007 crossref_primary_10_1002_jor_25861 crossref_primary_10_7759_cureus_10970 crossref_primary_10_1186_s12877_024_05498_w crossref_primary_10_1186_s12891_023_06662_w crossref_primary_10_1002_acr_25022 crossref_primary_10_1093_ptj_pzz164 crossref_primary_10_1136_bmjopen_2019_035805 crossref_primary_10_1002_art_40733 crossref_primary_10_1093_ijpp_riaf029 crossref_primary_10_2147_CIA_S442610 crossref_primary_10_1089_pop_2024_0037 crossref_primary_10_1016_j_otsm_2019_150708 crossref_primary_10_1016_j_intimp_2021_107657 crossref_primary_10_3389_fbioe_2020_00093 crossref_primary_10_15585_mmwr_mm7040a2 crossref_primary_10_1016_j_ijrobp_2022_04_029 crossref_primary_10_1007_s40122_022_00465_y crossref_primary_10_1177_0890117120981371 crossref_primary_10_1126_scitranslmed_aau8491 crossref_primary_10_1002_acr_25418 crossref_primary_10_1097_CORR_0000000000002554 crossref_primary_10_1002_adhm_202101479 crossref_primary_10_1088_1748_605X_abd1ba crossref_primary_10_1002_acr_24447 crossref_primary_10_1186_s12944_025_02618_2 crossref_primary_10_1302_0301_620X_101B7_BJJ_2018_1492_R1 crossref_primary_10_1002_hsr2_1989 crossref_primary_10_1371_journal_pone_0275656 crossref_primary_10_1007_s00256_022_04178_3 crossref_primary_10_1111_hsc_13110 crossref_primary_10_1186_s12891_022_05376_9 crossref_primary_10_4252_wjsc_v13_i7_825 crossref_primary_10_1007_s00223_020_00702_6 crossref_primary_10_1016_j_apmr_2020_04_001 crossref_primary_10_1038_s41423_023_01020_1 crossref_primary_10_1111_1541_4337_13374 crossref_primary_10_3390_diseases12080170 crossref_primary_10_1038_s41584_018_0058_9 crossref_primary_10_3390_ijms232416031 crossref_primary_10_1155_2018_2984671 crossref_primary_10_1016_j_jtherbio_2021_103172 crossref_primary_10_1097_TGR_0000000000000300 crossref_primary_10_1016_j_annepidem_2022_10_002 crossref_primary_10_1097_01_JAA_0000800260_99283_d3 crossref_primary_10_1016_j_mcna_2019_10_007 crossref_primary_10_3389_fvets_2023_1256284 crossref_primary_10_1177_01640275211044979 crossref_primary_10_1002_mabi_202200496 crossref_primary_10_1097_SAP_0000000000002271 crossref_primary_10_1007_s11926_023_01114_9 crossref_primary_10_1123_jab_2019_0031 crossref_primary_10_1016_j_jor_2025_07_028 crossref_primary_10_1016_j_jor_2020_03_016 crossref_primary_10_1080_09593985_2022_2118005 crossref_primary_10_1186_s12889_021_11570_6 crossref_primary_10_1007_s00256_024_04635_1 crossref_primary_10_1111_opn_70010 crossref_primary_10_3389_fpsyg_2020_01061 crossref_primary_10_3390_ijms21176046 crossref_primary_10_1017_S0144686X20000343 crossref_primary_10_1002_acr_25316 crossref_primary_10_1007_s40520_024_02847_y crossref_primary_10_1016_j_amepre_2025_02_010 crossref_primary_10_1096_fj_201901684RR crossref_primary_10_1080_14737167_2022_2117690 crossref_primary_10_1097_JOM_0000000000002568 crossref_primary_10_1186_s13223_023_00823_1 crossref_primary_10_1557_adv_2020_188 crossref_primary_10_4274_BMB_galenos_2023_2023_03_021 crossref_primary_10_2174_1381612825666190708184745 crossref_primary_10_1002_acr2_11090 crossref_primary_10_2147_JPR_S392840 crossref_primary_10_3390_nu13010053 |
| Cites_doi | 10.1097/MLR.0b013e318195fa79 10.1002/acr.22721 10.1002/art.20298 10.3899/jrheum.081068 10.1177/096228029600500305 10.5888/pcd10.120239 10.1002/acr.22943 10.1016/S0167-6296(01)00086-8 10.1002/1529-0131(200110)45:5<439::AID-ART363>3.0.CO;2-M 10.1111/j.1475-6773.2008.00909.x 10.1002/art.1790080403 10.1111/j.1475-6773.2009.00995.x 10.1002/1529-0131(200104)45:2<174::AID-ANR171>3.0.CO;2-1 10.1002/acr.20347 10.1002/art.22565 |
| ContentType | Journal Article |
| Copyright | 2017, American College of Rheumatology 2017, American College of Rheumatology. 2018 American College of Rheumatology |
| Copyright_xml | – notice: 2017, American College of Rheumatology – notice: 2017, American College of Rheumatology. – notice: 2018 American College of Rheumatology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP NAPCQ 7X8 |
| DOI | 10.1002/acr.23425 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Nursing & Allied Health Premium |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2151-4658 |
| EndPage | 876 |
| ExternalDocumentID | 28950426 10_1002_acr_23425 ACR23425 |
| Genre | article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: National Association of Chronic Disease Directors funderid: 3332015 – fundername: CDC funderid: 2009‐M‐32656; 200‐2012‐M‐51533 |
| GroupedDBID | .3N .GA .Y3 0R~ 10A 1OC 31~ 33P 4.4 50Z 51W 51X 52N 52O 52P 52R 52S 52T 52W 52X 53G 5VS 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABIJN ABJNI ABQWH ABXGK ACAHQ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIDQK AIDYY AITYG AIURR ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BRXPI BY8 D-6 D-7 D-E D-F DCZOG DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S GODZA H.X HF~ HGLYW HZ~ J0M J5H KBYEO LATKE LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D Q.N QB0 ROL SUPJJ TEORI UB1 V9Y W8V W99 WBKPD WHWMO WIK WOHZO WQJ WVDHM WXI WXSBR XG1 ZZTAW ~WT AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7QP NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c3535-f93c42d0f43efe31ae6306f7d11f335986a1cde17266e32184877e1a4840bd683 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 176 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000434049700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2151-464X 2151-4658 |
| IngestDate | Thu Jul 10 19:16:48 EDT 2025 Sun Jul 13 03:55:06 EDT 2025 Mon Jul 21 05:58:10 EDT 2025 Sat Nov 29 07:20:49 EST 2025 Tue Nov 18 22:30:27 EST 2025 Sun Sep 21 06:19:58 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | 2017, American College of Rheumatology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3535-f93c42d0f43efe31ae6306f7d11f335986a1cde17266e32184877e1a4840bd683 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3919-0721 |
| PMID | 28950426 |
| PQID | 2047383729 |
| PQPubID | 2045195 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1943646938 proquest_journals_2047383729 pubmed_primary_28950426 crossref_citationtrail_10_1002_acr_23425 crossref_primary_10_1002_acr_23425 wiley_primary_10_1002_acr_23425_ACR23425 |
| PublicationCentury | 2000 |
| PublicationDate | June 2018 2018-06-00 20180601 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: June 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Arthritis care & research (2010) |
| PublicationTitleAlternate | Arthritis Care Res (Hoboken) |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2009; 44 2009; 47 2012 2011 2017; 69 2010 1983; 1 2002; 8 2008 2007 2006 1995 2001; 45 2007; 56 2001; 20 1995; 8 2009; 36 2004; 50 2013; 10 2006; 28 2011; 63 2005; 32 2016 2015 2014 2013 1996; 5 2016; 68 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 SAS Institute (e_1_2_6_19_1) Harrington P (e_1_2_6_32_1) 2002; 8 Sacks JJ (e_1_2_6_27_1) 2005; 32 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 Duan N (e_1_2_6_17_1) 1983; 1 e_1_2_6_21_1 e_1_2_6_20_1 Sing M (e_1_2_6_29_1) 2006; 28 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_28_1 e_1_2_6_26_1 |
| References_xml | – year: 2011 – volume: 8 start-page: 203 year: 1995 end-page: 11 article-title: Arthritis and other rheumatic conditions: who is affected now, who will be affected later? National Arthritis Data Workgroup publication-title: Arthritis Care Res – volume: 44 start-page: 1679 year: 2009 end-page: 700 article-title: Validating household reports of health care use in the Medical Expenditure Panel Survey publication-title: Health Serv Res – volume: 68 start-page: 574 year: 2016 end-page: 80 article-title: Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population‐based survey publication-title: Arthritis Care Res (Hoboken) – volume: 10 start-page: E66 year: 2013 article-title: Defining and measuring chronic conditions: imperatives for research, policy, program, and practice publication-title: Prev Chronic Dis – volume: 45 start-page: 439 year: 2001 end-page: 45 article-title: Inactivity‐associated medical costs among US adults with arthritis publication-title: Arthritis Rheum – year: 2007 – volume: 8 start-page: 499 year: 2002 end-page: 508 article-title: Analysis of the movement of prescription drugs to over‐the‐counter status publication-title: J Manag Care Pharm – volume: 44 start-page: 303 year: 2009 end-page: 20 article-title: Comparing cost‐of‐illness estimates from alternative approaches: an application to diabetes publication-title: Health Serv Res – volume: 28 start-page: 25 year: 2006 end-page: 40 article-title: Reconciling medical expenditure estimates from the MEPS and NHEA, 2002 publication-title: Health Care Financ Rev – volume: 5 start-page: 283 year: 1996 end-page: 310 article-title: Variance estimation for complex surveys using replication techniques publication-title: Stat Methods Med Res – year: 2016 – year: 2014 – start-page: 4845 year: 2012 end-page: 59 – year: 2010 – volume: 20 start-page: 461 year: 2001 end-page: 94 article-title: Estimating log models: to transform or not to transform? publication-title: J Health Econ – volume: 47 start-page: 618 year: 2009 end-page: 25 article-title: Sensitivity of household reported medical conditions in the medical expenditure panel survey publication-title: Med Care – volume: 69 start-page: 356 year: 2017 end-page: 67 article-title: Defining arthritis for public health surveillance: methods and estimates in four US population health surveys publication-title: Arthritis Care Res (Hoboken) – volume: 50 start-page: 2317 year: 2004 end-page: 26 article-title: Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates publication-title: Arthritis Rheum – year: 2008 – year: 2006 – volume: 56 start-page: 1397 year: 2007 end-page: 407 article-title: Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997 publication-title: Arthritis Rheum – year: 1995 – volume: 32 start-page: 340 year: 2005 end-page: 7 article-title: Validation of a surveillance case definition for arthritis publication-title: J Rheumatol – volume: 36 start-page: 2531 year: 2009 end-page: 8 article-title: Trends in medical care expenditures of US adults with arthritis and other rheumatic conditions 1997 to 2005 publication-title: J Rheumatol – volume: 1 start-page: 115 year: 1983 end-page: 26 article-title: A comparison of alternative models for the demand for medical care publication-title: J Bus Econ – year: 2015 – volume: 45 start-page: 174 year: 2001 end-page: 82 article-title: Use of the Americans with Disabilities Act by persons with rheumatic diseases and factors associated with use publication-title: Arthritis Rheum – year: 2013 – volume: 63 start-page: 79 year: 2011 end-page: 93 article-title: Effects of community‐deliverable exercise on pain and physical function in adults with arthritis and other rheumatic diseases: a meta‐analysis publication-title: Arthritis Care Res (Hoboken) – ident: e_1_2_6_20_1 – ident: e_1_2_6_23_1 – ident: e_1_2_6_26_1 – ident: e_1_2_6_33_1 doi: 10.1097/MLR.0b013e318195fa79 – ident: e_1_2_6_10_1 doi: 10.1002/acr.22721 – ident: e_1_2_6_34_1 – volume: 28 start-page: 25 year: 2006 ident: e_1_2_6_29_1 article-title: Reconciling medical expenditure estimates from the MEPS and NHEA, 2002 publication-title: Health Care Financ Rev – ident: e_1_2_6_11_1 – ident: e_1_2_6_14_1 – ident: e_1_2_6_28_1 – ident: e_1_2_6_2_1 doi: 10.1002/art.20298 – ident: e_1_2_6_22_1 – ident: e_1_2_6_3_1 doi: 10.3899/jrheum.081068 – ident: e_1_2_6_39_1 – ident: e_1_2_6_7_1 – volume: 1 start-page: 115 year: 1983 ident: e_1_2_6_17_1 article-title: A comparison of alternative models for the demand for medical care publication-title: J Bus Econ – ident: e_1_2_6_21_1 doi: 10.1177/096228029600500305 – ident: e_1_2_6_12_1 doi: 10.5888/pcd10.120239 – ident: e_1_2_6_9_1 doi: 10.1002/acr.22943 – ident: e_1_2_6_18_1 doi: 10.1016/S0167-6296(01)00086-8 – ident: e_1_2_6_5_1 – volume: 8 start-page: 499 year: 2002 ident: e_1_2_6_32_1 article-title: Analysis of the movement of prescription drugs to over‐the‐counter status publication-title: J Manag Care Pharm – ident: e_1_2_6_38_1 doi: 10.1002/1529-0131(200110)45:5<439::AID-ART363>3.0.CO;2-M – ident: e_1_2_6_30_1 – ident: e_1_2_6_13_1 doi: 10.1111/j.1475-6773.2008.00909.x – ident: e_1_2_6_25_1 doi: 10.1002/art.1790080403 – ident: e_1_2_6_24_1 – ident: e_1_2_6_31_1 doi: 10.1111/j.1475-6773.2009.00995.x – ident: e_1_2_6_16_1 – ident: e_1_2_6_8_1 – ident: e_1_2_6_36_1 doi: 10.1002/1529-0131(200104)45:2<174::AID-ANR171>3.0.CO;2-1 – ident: e_1_2_6_37_1 doi: 10.1002/acr.20347 – ident: e_1_2_6_6_1 – ident: e_1_2_6_35_1 – volume-title: SAS 9.3 help and documentation ident: e_1_2_6_19_1 – volume: 32 start-page: 340 year: 2005 ident: e_1_2_6_27_1 article-title: Validation of a surveillance case definition for arthritis publication-title: J Rheumatol – ident: e_1_2_6_4_1 doi: 10.1002/art.22565 – ident: e_1_2_6_15_1 |
| SSID | ssj0000328839 |
| Score | 2.6094189 |
| Snippet | Objective
We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.
Methods
We calculated... We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data. We calculated arthritis-attributable and all-cause... ObjectiveWe estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.MethodsWe calculated arthritis‐attributable... We estimated the economic impact of arthritis using 2013 US Medical Expenditure Panel Survey (MEPS) data.OBJECTIVEWe estimated the economic impact of arthritis... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 869 |
| SubjectTerms | Adolescent Adult Ambulatory care Arthritis Arthritis - economics Chronic illnesses Cost of Illness Cross-Sectional Studies Earnings Expenditures Health Expenditures - statistics & numerical data Humans Income Middle Aged Pain Sensitivity analysis Young Adult |
| Title | Medical Expenditures and Earnings Losses Among US Adults With Arthritis in 2013 |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr.23425 https://www.ncbi.nlm.nih.gov/pubmed/28950426 https://www.proquest.com/docview/2047383729 https://www.proquest.com/docview/1943646938 |
| Volume | 70 |
| WOSCitedRecordID | wos000434049700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 2151-4658 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000328839 issn: 2151-464X databaseCode: DRFUL dateStart: 20100101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1RT9swED5BQRMv24CxdWPIIB54yZrYju1oTxWj2kMHCCjrW-Q6tkCaUtTQ_f7dJWkmtCFN2lukOLHlu_Pdd5d8B3BspXGxn-Hph94HAYqNI8s1ldi1DGkoeFF3nrsd6_NzM51ml2vwefUvTMMP0SXcyDLq85oM3M6qwW_SUOsWn7hAlVuHDY56m_Zg48vVaDLuUixEFWfqXmLk1yKp5HTFLRTzQff8U4_0R5j5NGqt3c7o1X8t-DW8bKNNNmzUYxvWfLkDL7619fRduGjrNIwYj6l4vUT0zWxZsLMmY1Kx8ZzKwmxITYnY5JoNibCjYt_vH-_ovXc1KRK7Lxn6ePEGJqOzm9OvUdtiIXIiFWkUMuEkL-IghQ9eJNYrxBBBF0kSBJH7KZu4wmOUo5QXBAeN1j5BCct4Vigj9qBXzkv_DpgJGcKjAhGRDtIbb0OmnLAupHhmZD7rw8lqm3PX8o9TG4wfecOczHPcoLzeoD4cdUMfGtKNvw3aX8kqb-2uynksNWFujtMddrfRYqgMYks_X1Z5kkmhpMqE6cPbRsbdLAg_U0KVuNhalM9Pnw9Pr-qL9_8-9ANsoSxM86XZPvQeF0v_ETbdTxTU4gDW9dQctEr8C8vM7wg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fT9swED7xY2K8wDZgFNjmoT3wkpHEjuNIvFRAxbTQIUa3vlnGsQXSlE4t5e_nLkmDECAh8RYpTmz57nz33SXfAXwzQtnQXeLph94HAYoJAxOnVGJPhU98ERdV57k_edrvq-EwO5uDg9m_MDU_RJtwI8uozmsycEpI79-zhho7_h5z1Ll5WBSoRqjfi0fnvUHe5liIK05VzcTIsQVCiuGMXCiM99vnH7qkR3Hmw7C18ju91det-B2sNPEm69YK8h7mXPkBlk6bivoa_GoqNYw4j6l8PUX8zUxZsOM6ZzJh-YgKw6xLbYnY4DfrEmXHhP29vrmi915VtEjsumTo5fk6DHrHF4cnQdNkIbA84UngM25FXIRecOcdj4yTiCJ8WkSR50TvJ01kC4dxjpSOEyBUaeoilLEILwup-AYslKPSbQJTPkOAVCAmSr1wyhmfScuN9QmeGpnLOrA322dtGwZyaoTxT9fcybHGDdLVBnVgtx36v6bdeGrQzkxYurG8iY5DkRLqjnG6r-1ttBkqhJjSjaYTHWWCSyEzrjrwsRZyOwsC0IRwJS62kuXz0-vu4Xl1sfXyoV_g7cnFaa7zH_2f27CMclH1d2c7sHAznrpP8MbeotDGnxtdvgOGbfIQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT9swFH-CMqFdBtvYKDDmTRx2yUhix3EkLhVQMa3rEKyjN8v4QyChFLV0fz_vJWkQ2iYhcYsUJ7b8Pn9-ye8B7BmhbOwv0fth9EGAYuLIpDmV2HMRsuBSV3We-z3Ih0M1HhenS3Cw-Bem5odoD9zIMip_TQbub13Yf2ANNXb6NeWoc8uwIqiJTAdWjs76o0F7xkJccapqJkaBLRJSjBfkQnG63z7_OCT9lWc-TluruNNfe96K1-FVk2-yXq0gr2HJl29g9UdTUX8LP5tKDSPOYypfzxF_M1M6dlyfmczYYEKFYdajtkRsdM56RNkxYxfXd1f03quKFoldlwyjPN-AUf_41-FJ1DRZiCzPeBaFgluRujgI7oPnifESUUTIXZIETvR-0iTWecxzpPScAKHKc5-gjEV86aTi76BTTkq_CUyFAgGSQ0yUB-GVN6GQlhsbMvQahS-68GWxz9o2DOTUCONG19zJqcYN0tUGdeFzO_S2pt3416CdhbB0Y3kzncYiJ9Sd4nSf2ttoM1QIMaWfzGc6KQSXQhZcdeF9LeR2FgSgGeFKXGwly_9Pr3uHZ9XF1tOHfoTV06O-Hnwbft-GlygWVX92tgOdu-ncf4AX9g_KbLrbqPI9JHDxiw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Medical+Expenditures+and+Earnings+Losses+Among+US+Adults+With+Arthritis+in+2013&rft.jtitle=Arthritis+care+%26+research+%282010%29&rft.au=Murphy%2C+Louise+B.&rft.au=Cisternas%2C+Miriam+G.&rft.au=Pasta%2C+David+J.&rft.au=Helmick%2C+Charles+G.&rft.date=2018-06-01&rft.issn=2151-464X&rft.eissn=2151-4658&rft.volume=70&rft.issue=6&rft.spage=869&rft.epage=876&rft_id=info:doi/10.1002%2Facr.23425&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_acr_23425 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2151-464X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2151-464X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2151-464X&client=summon |